Navigation Links
Senetek PLC Investor Hotline Goes Live
Date:5/15/2009

Call 877-SENETEK or 707-259-6278

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced that an up-to-date audio recording of Company news and developments is now available by calling 877-SENETEK in the United States and Canada and 707-259-6278 from international locations.

"We are pleased to provide this service to our investors as a supplement to news releases, shareholder teleconferences and our quarterly and annual filings. Our mission is to keep the Senetek shareholder updated in a timely fashion," stated Frank J. Massino, Chairman and Chief Executive Officer of Senetek.

About Senetek PLC:

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites:

www.senetekplc.com

www.pyratine6.com

www.pyratinexr.com

or call: 877-SENETEK (United States and Canada) 707-259-6278 (International Locations)

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Announces New Investor Communication Hotline
2. Senetek PLC Announces 2008 Annual General Meeting Voting Results
3. Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
4. Senetek Affirms Strong Financial Position
5. Senetek PLC Reports Second Quarter 2008 Financial Results
6. Senetek PLC Reports First Quarter 2008 Financial Results
7. Senetek PLC Announces Appointments of Key Personnel
8. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
11. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... system to find a better treatment for triple negative breast ... in France program. The ... an accelerator designed to help entrepreneurs grow their business in ... one of eight American companies selected to complete an intensive ...
(Date:2/16/2017)... Research and Markets has announced ... report to their offering. ... The study ... delivery plasmids, chassis organisms, synthetic cells, production systems), enabling ... bioinformatics and specialty media) and enabled technologies (biofuels, chemicals, ...
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) ... nodule patient management. In addition to optimizing care coordination ... the lung, UCHealth looks to improve provider workflow by ... Stephanie Brown, RN , Thoracic Nurse Navigator, ... an Excel spreadsheet, which was extremely arduous and susceptible ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/25/2017)... NEW YORK , Jan. 25, 2017 /PRNewswire/ ... and Access Management (IAM) lifecycle is comprised of ... infrastructure for the purpose of maintaining digital identities ... enterprise resources and applications. There are significant number ... compliance from time to time by optimizing processes ...
Breaking Biology News(10 mins):